Passively administered anti-tumor monoclonal antibodies (mAbs) rapidly kill tumor targets via FcgRmediated cytotoxicity (ADCC), a short-term process. However, anti-tumor mAb treatment can also induce a vaccinal effect, in which mAb-mediated tumor death induces a long-term anti-tumor cellular immune response. To determine how such responses are generated, we utilized a murine model of an anti-tumor vaccinal effect against a model neoantigen. We demonstrate that FcgR expression by CD11c + antigen-presenting cells is required to generate antitumor T cell responses upon ADCC-mediated tumor clearance. Using FcgR-humanized mice, we demonstrate that anti-tumor human (h)IgG1 must engage hFcgRIIIA on macrophages to mediate ADCC, but also engage hFcgRIIA, the sole hFcgR expressed by human dendritic cells (DCs), to generate a potent vaccinal effect. Thus, while next-generation antitumor antibodies with enhanced binding to only hFcgRIIIA are now in clinical use, ideal anti-tumor antibodies must be optimized for both cytotoxic effects as well as hFcgRIIA engagement on DCs to stimulate long-term anti-tumor cellular immunity.
INTRODUCTION
Passive administration of anti-tumor antibodies is an important clinical tool for the management of a variety of cancers (Pincetic et al., 2014) and generally functions by targeting malignant cells through Fc-receptor for IgG (FcgR)-mediated antibodydependent cellular cytotoxicity (ADCC) by myeloid effector cells (Clynes et al., 2000; Taylor and Lindorfer, 2008; Uchida et al., 2004) or possibly natural killer (NK) cells. Because of this FcgR-mediated mechanism of action, next-generation versions of anti-tumor mAbs that have been Fc-engineered for enhanced engagement of activating hFcgRIIIA are now being used in the clinic or are under investigation (Goede et al., 2014) . However, while ADCC-mediated tumor killing is rapid and relatively short-acting, patients with some malignancies see long-term responses after cessation of antibody therapy; this has prompted the hypothesis that a vaccinal or auto-immunization effect is initiated, in which tumor targeting by a monoclonal antibody (mAb) primes the patient's immune system to generate an anti-tumor T cell memory response (Cartron et al., 2004) . Thus, it has been demonstrated that cellular immune responses are generated in both mice and patients treated with anti-HER-2/neu mAb (Park et al., 2010; Taylor et al., 2007) . Anti-MUC1 cellular immune responses have also been reported after the use of anti-MUC1 mAb in patients with MUC1 + tumors (de Bono et al., 2004) . Evidence in lymphoma patients suggests that a vaccinal effect can be generated by anti-human (h)CD20 mAb immunotherapy (rituximab), since a single course of treatment with mAb can result in long-lasting, durable responses (Cartron et al., 2004) . In support of this, it has been reported that some patients treated with rituximab developed lymphoma-specific antiidiotype T cell responses after mAb treatment (Hilchey et al., 2009) . Recent studies in mice have also demonstrated that passive administration of anti-CD20 mAbs can initiate anti-tumor cellular immune responses (Abè s et al., 2010) . Therefore, while the hypothesis of a tumor-specific antibody-induced anti-tumor vaccinal effect has persisted for more than a decade, an experimentally derived mechanistic explanation is lacking. New technologies have enabled the identification of tumor mutational signatures, some common across multiple cancer types while others are restricted to specific malignancies (Alexandrov et al., 2013) . Thus, mutation-induced, developmentally restricted, or overexpressed tumor neoantigens are a major target of tumor-infiltrating lymphocytes in patients (Fritsch et al., 2014; Tran et al., 2014) . Neoantigen-specific CD4 + and CD8 + T cells have been identified, showing that such antigens are indeed processed and presented van Rooij et al., 2013) . Further, new immune-checkpoint blockade therapies function in patients by amplifying neoantigen-specific responses (van Rooij et al., 2013) . However, although studies analyzing antibody responses to tumor neoantigens are lacking, antibody:antigen immune complexes can stimulate cellular immunity by engaging activating FcgRs on antigen-presenting cells, such as dendritic cells (DCs), to induce DC maturation, traditional antigen presentation and cross-presentation, costimulatory molecule upregulation, and stimulate cellular immune responses in both mice (Kalergis and Ravetch, 2002; Rafiq et al., 2002) and humans (Boruchov et al., 2005; Dhodapkar et al., 2005) . Often, antibody:antigen immune complex immunization results in more potent cross-presentation and CD4 or CD8 T cell responses than antigen immunization alone. Thus, a logical approach to boosting cellular immune responses involves passive administration of antibodies reactive with tumor antigens or tumor neoantigens. Therefore, in this current study, we utilize a tumor model expressing a model tumor neoantigen to test whether and how passive anti-tumor antibody treatment stimulates an anti-tumor vaccinal effect and cellular immune response. Three activating FcgRs are expressed in mice (mouse [m]FcgRI, mFcgRIII, and mFcgRIV) and humans (hFcgRI, hFcgRIIA, and hFcgRIIIA), and a single inhibitory FcgR, FcgRIIB, is expressed in both species. The cellular outcome of IgG interactions with FcgRs is governed by the affinity of an antibody's Fc for the specific receptor and the expression pattern of those receptors on effector cells . Since most effector cells co-express activation and inhibitory FcgRs, it is the ratio of the binding affinities of a specific IgG Fc to these receptors that will determine the outcome of the IgG-FcgR interaction. These binding affinities are determined by the amino acid sequences of the IgG Fc subclasses and the IgG Fc's N-linked glycan. The IgG Fc composition can dramatically influence the in vivo outcome of engaging a tumor antigen by directing the antibody-antigen immune complex or opsonized cell into either a pro-or anti-inflammatory response. For example, mIgG2a antibodies trigger cytotoxicity by virtue of this Fc having a 2-log greater affinity for the activating mFcgRIV receptor as compared to the inhibitory mFcgRIIb receptor, while mIgG1 preferentially engages the inhibitory mFcgRIIb receptor.
Mice and humans differ regarding the specific FcgRs expressed on various antigen-presenting cells and the relative affinities of each IgG Fc subclass for each FcgR (Nimmerjahn and Ravetch, 2007) . Thus, hIgG1 Fc does not preferentially engage a single hFcgR, as occurs in mice. Two low-affinity activating FcgRs are expressed on monocytes and macrophages in both mice (mFcgRIII and mFcgRIV) and humans (hFcgRIIA and hFcgRIIIA). Murine NK cells express only mFcgRIII, while human NK cells express only hFcgRIIIA. Importantly, while mice express two low-affinity activating FcgRs, mFcgRIII and mFcgRIV, on DCs, humans only express one low-affinity activating FcgR on DCs, hFcgRIIA. Because of these species differences, we have generated FcgR-humanized mice, which express the full array of hFcgRs on a background lacking all murine FcgRs . Appropriate cell-type-specific expression of all hFcgRs is observed in the FcgR-humanized mice, allowing the characterization of hIgG1 antibody-mediated effector function in the context of human FcgRs.
Here, using a murine lymphoma expressing a model tumor neoantigen (hCD20), we mechanistically dissect how an antitumor cellular immune response is generated after passive treatment of lymphoma-bearing mice with anti-hCD20 mAb. We demonstrate that not only are activating FcgRs required for macrophage-mediated ADCC, but activating FcgR expression specifically on CD11c + antigen-presenting cells is required for the generation of an anti-tumor T cell memory immune response and long-term survival. Because of the complexity of the FcgR system, with multiple genes expressed and regulated differentially on the diverse cells of the immune system, designing an anti-tumor antibody for optimal activity requires compatible model systems. We therefore assessed the generation of an anti-tumor vaccinal effect for a hIgG1 anti-hCD20 mAb in FcgR-humanized mice. We show that anti-tumor mAb must engage hFcgRIIIA on clodronate liposome (CLOD)-sensitive macrophages to mediate immediate ADCC, as well as hFcgRIIA (the sole FcgR expressed by human DCs) in order to stimulate a long-term anti-tumor cellular immune response. Thus, while next-generation anti-tumor antibodies with enhanced binding to only hFcgRIIIA on innate effector cells are now in clinical use, our results indicate that anti-tumor antibodies with optimal long-term survival benefit must be optimized for both their short-acting cytotoxic effects through hFcgRIIIA, as well as for engagement of hFcgRIIA on DCs to stimulate long-term antitumor cellular immunity.
RESULTS

Generation of an Anti-tumor Vaccinal Effect by Passive Anti-tumor Antibody Treatment
To understand how passive anti-tumor mAb treatment can induce long-term anti-tumor cellular immune responses, we adapted a murine lymphoma model (Abè s et al., 2010) of an anti-neoantigen mAb-mediated vaccinal effect ( Figure 1A ). Wild-type C57BL/6 mice were given syngenic EL4 lymphoma cells that express hCD20 as a tumor neoantigen (EL4-hCD20 cells), followed by mIgG2a isotype anti-hCD20 mAb. The mIgG2a isotype preferentially engages activating mFcgRs and is the most potent mouse subclass for triggering effector cells to result in cellular cytotoxicity, phagocytosis, and inflammatory responses Pincetic et al., 2014) . Mice receiving lymphoma cells plus anti-hCD20 mAb clear the tumors and survive in an activating FcgR-dependent manner; wild-type mice survive the tumor challenge, while FcRa null mice (that lack all mFcgRs: mFcgRI, mFcgRIIB, mFcgRIII, and mFcgRIV) and Fcer1g À/À mice (that lack all activating mFcgRs: mFcgRI, mFcgRIII, and mFcgRIV) do not ( Figures 1B and S1A ). The activating mFcgRIV is a major contributor during this clearance of tumor cells, since only 52% of Fcgr4 À/À mice survive tumor challenge after anti-hCD20 mAb treatment (p < 0.001; Figure S1B ). Non-FcgR binding DA265 mutant anti-hCD20 was also unable to clear tumors ( Figure S1C ). Thus, activating FcgRs mediate the initial ADCC clearance of tumor cells by anti-tumor mAb, as reported (Clynes et al., 2000; Uchida et al., 2004) . We next assessed whether an anti-tumor vaccinal effect was generated in mice that survived the initial EL4-hCD20 challenge via treatment with anti-hCD20 mAb. Ninety days after the initial challenge when anti-hCD20 mAb had been cleared (mIgG2a half-life = 7 days) (Vieira and Rajewsky, 1988) , surviving tumor/mAb-primed mice were re-challenged with 5 3 10 6 EL4-hCD20 tumor cells, a dose that is 10-fold greater than the initial challenge, without treatment with any additional anti-hCD20 mAb. These primed mice showed 100% survival during re-challenge with EL4-hCD20 cells ( Figure 1C ). By contrast, surviving tumor/mAb-primed mice re-challenged with EL4-WT cells, which do not express hCD20, showed poor survival. Similar results were seen using a different anti-hCD20 mAb, clone 2B8, which is the parental hybridoma from which rituximab was generated ( Figures S1D and S1E) . Thus, mice primed with EL4-hCD20 and anti-hCD20 mAb generate a memory immune response and subsequently reject re-challenge with EL4-hCD20 cells, but not EL4 WT cells.
In this model of the vaccinal effect, both CD4 + and CD8 + T cells are required after antibody treatment in order to reject the tumor re-challenge (Abè s et al., 2010) . Specifically, T cell depletion studies demonstrated that CD4 + T cells are required during the initial phases of antibody therapy as well as during tumor re-challenge in order to reject tumors. Using CD8-deficient mice, it was also shown that CD8 + cells are required for tumor rejection during re-challenge. By contrast, mice do not mount any detectable antibody response against hCD20 or EL4-hCD20 cells, and adoptive transfer of serum from tumor/ mAb-primed mice does not protect against tumor challenge (Abè s et al., 2010) . In Figure 1C , we show that EL4-hCD20/ anti-hCD20 mAb-primed mice only reject EL4-hCD20 cells, and not wild-type EL4 cells, suggesting that the vaccinal effect is directed against hCD20, with little detectable antigen spreading. To confirm that at least a portion of the vaccinal effect cellular immune response is directed at hCD20, mice primed with EL4-hCD20 cells and anti-hCD20 mAb were re-challenged with a distinct tumor cell line, B6BL lymphoma cells, that expressed either cell-surface hCD20 or an irrelevant antigen (mCD20). While 100% of mice re-challenged with B6BL-mCD20 died by day 31, 80% of mice re-challenged with B6BL-hCD20 cells survived at least 90 days ( Figure 1D ; p = 0.0001). Thus, only cells expressing hCD20 were capable of being rejected. Collectively, these experiments demonstrate that an antihCD20 immune response is generated after the initial FcgRmediated clearance of tumor cells by ADCC.
Expression of mFcgRIV on CD11c
+ Cells Is Required for the Generation of an Anti-tumor Vaccinal Effect To understand the mechanistic basis for an anti-tumor vaccinal effect and to determine whether FcgR expression plays a role during this process, we utilized mice with a CD11c + cell-specific deletion of mFcgRIV. Fcgr4 fl/fl;cd11c-cre mice (Nimmerjahn et al., 2010) show a complete absence of mFcgRIV expression on spleen CD11c hi DCs, but only a partial decrease in mFcgRIV expression on spleen CD11b + Gr-1 lo SSC lo monocytes ( Figure 2A ). All CD11c hi cells lose mFcgRIV expression in Fcgr4 fl/fl;cd11c-cre mice, while spleen CD11c int cells show partial loss of mFcgRIV and CD11c
À cells show only a modest decrease in mFcgRIV ( Figure S2A ; Table S1 ). The majority of CD11c S4 , and S5; Table S1 ). Therefore, because mFcgRIV expression was maintained to a sufficient degree on ADCC-mediating innate cells, both control Fcgr4 fl/fl and Fcgr4 fl/fl;cd11c-cre mice were able to clear primary EL4-hCD20 lymphoma cell challenge after treatment with anti-hCD20 mAb ( Figure 2B ), indicating that mFcgRIV expression on CD11c + cells is not required for anti-hCD20 mAb-mediated ADCC.
To assess the generation of the anti-hCD20 vaccinal effect in the context of CD11c + cells lacking mFcgRIV, surviving tumor/mAbprimed Fcgr4 fl/fl and Fcgr4 fl/fl;cd11c-cre mice were re-challenged with EL4-hCD20 cells. Re-challenge of primed Fcgr4 fl/fl mice resulted in 100% survival ( Figure 2C ). By contrast, only 57% of tumor/mAb-primed Fcgr4 fl/fl;cd11c-cre mice survived re-challenge with EL4-hCD20 cells (p = 0.0069). It is likely that activating mFcgRIII, which is also expressed on murine DCs, compensates in the absence of mFcgRIV, thereby explaining why a modest vaccinal effect remains in Fcgr4 fl/fl;cd11c-cre mice. Thus, expression of the IgG2a-preferential activating mFcgRIV on CD11c + antigenpresenting cells is required for the generation of the anti-tumor vaccinal effect after mAb-mediated killing of tumor cells.
CD11c + Cell Expression of mFcgRIV Is Required to Generate Anti-tumor Cellular Immunity
To quantify anti-tumor cellular immunity in vivo, we performed adoptive transfer experiments ( Figure 3A ). Mice were given EL4-hCD20 cells and mIgG2a anti-hCD20 mAb, with spleens harvested and total splenocytes or CD3 + T cells isolated and adoptively transferred into naive mice that were then challenged with EL4-hCD20 cells. Adoptive transfer of splenocytes or T cells from naive mice was unable to protect against tumor growth, but transfer of splenocytes or T cells from tumor/mAb-primed mice resulted in 80% (p = 0.0044) and 75% (p = 0.0067) survival, respectively ( Figure 3B ). Thus, tumor/mAb-primed mice generate a quantifiable anti-tumor T cell response.
To determine whether DC expression of mFcgRIV is required for the generation of the anti-tumor cellular immune response after passive administration of anti-tumor mAb, tumor/mAbprimed splenocytes from Fcgr4 fl/fl and Fcgr4 fl/fl;cd11c-cre mice were adoptively transferred into naive mice before challenge with EL4-hCD20 cells. While 76% of mice receiving splenocytes from tumor/mAb-primed Fcgr4 fl/fl mice survived EL4-hCD20 challenge, only 34% of tumor/mAb-primed Fcgr4 fl/fl;cd11c-cre mice survived the challenge (p = 0.0041; Figure 3C ). Thus, expression of mFcgRIV on CD11c + antigen-presenting cells is required to mediate the generation of an anti-tumor cellular immune response after mAb-mediated clearance of tumor. were given EL4-hCD20 cells and treated with mIgG2a anti-hCD20 mAb, with survival monitored daily. (C) After 90 days, surviving Fcgr4 fl/fl (green circles) or Fcgr4 fl/fl;cd11c-cre (blue squares) mice treated with mIgG2a isotype anti-hCD20 mAb from (B) were rechallenged with EL4-hCD20 cells, with survival assessed daily (n = 14-16 mice per group). Significant differences between groups are indicated: **p = 0.0065; n.s., not significant. See also Table S1 .
immune cells, and signaling properties (Nimmerjahn and Ravetch, 2006; Pincetic et al., 2014) . For example, NK cells in the mouse express only mFcgRIII, a low-affinity activating FcgR. Macrophages and DCs express distinct combinations of both activating (mFcgRI, mFcgRIII, and mFcgRIV) and inhibitory (mFcgRIIB) receptors. Individual mouse subclasses show preferential mFcgR binding affinities, with mIgG1 preferentially engaging the inhibitory mFcgRIIB while mIgG2a engages the activating receptor mFcgRIV with a 2 log higher affinity Ravetch, 2008, 2011) . Thus, selecting an antibody for optimal FcgR engagement requires consideration of the receptors and cell types that are to be engaged. Further complicating this situation are the inter-species differences between mice and humans. Human FcgR genes, expression patterns, and affinities for the various antibody isotypes differ significantly from mice. Importantly, humans express only the low-affinity activating FcgR-FcgRIIIA-on NK cells, the cells that are thought to primarily mediate cellular cytotoxicity in humans (Seidel et al., 2013) , while antigen-presenting DCs express a single, distinct low-affinity activating FcgR, hFcgRIIA (Boruchov et al., 2005; Nimmerjahn and Ravetch, 2008) . Therefore, to engineer an antibody to optimize the generation of an anti-tumor vaccinal effect initiated by a hIgG1 antibody in the context of hFcgRs, we utilized FcgR-humanized mice, which express the full array of hFcgRs on a fully immunocompetent C57BL/6 background lacking all mFcgRs (Bournazos et al., 2014a; Smith et al., 2012 S6A , and S6B).
To address the relative contributions of individual hFcgRs during mAb-mediated clearance of primary tumor challenge and during the generation of an anti-tumor vaccinal effect, we generated anti-hCD20 mAb with a hIgG1 Fc backbone and introduced known point mutations (Bournazos et al., 2014b; DiLillo et al., 2014; Smith et al., 2012) that selectively enhance interactions with individual hFcgRs ( Figure 5A ; Table S2 ). Thus, the G236A (GA) mutant shows selectively enhanced binding to hFcgRIIA, the A330L/I332E (ALIE) mutant shows selectively enhanced binding to hFcgRIIIA, and the G236A/S239D/A330L/I332E (GAS-DALIE) mutant shows dramatically enhanced engagement to both hFcgRIIA and hFcgRIIIA.
To determine which hFcgRs are responsible for the initial ADCC-mediated clearance of tumor cells, FcgR-humanized mice were given EL4-hCD20 lymphoma cells and were treated with the various Fc-engineered hIgG1 anti-hCD20 mAbs. The GA mutant anti-hCD20 mAb that selectively engages hFcgRIIA was unable to clear tumor, as 81% of mice receiving this antibody died after primary tumor challenge ( Figure 5B ). By contrast, 82% and 85% of mice receiving ALIE mutant (selectively engaging hFcgRIIIA) and GASDALIE mutant (selectively enhance both hFcgRIIA and hFcgRIIIA) anti-hCD20 mAb survived the primary EL4-hCD20 tumor challenge, respectively. Further, mice expressing only hFcgRIIA (deficient for murine FcgRs) were unable to clear the primary tumor challenge after mAb treatment, while mice expressing only hFcgRIIIA and hFcgRIIIB (deficient for murine FcgRs) showed full survival when treated with GASDALIE mutant anti-hCD20 mAb ( Figure 5C ). Notably, wild-type hIgG1 anti-hCD20 mAb does not protect FcgRhumanized mice or mice expressing either hFcgRIIA or hFcgRIIIA/B from EL4-hCD20 tumor challenge ( Figures S6C  and S6D ), indicating that wild-type interactions between these hFcgRs and hIgG1 provide insufficient signaling to mediate effector functions at the doses used in this mouse model. Taken together, these results demonstrate that while hFcgRIIA is dispensable, hFcgRIIIA is both necessary and sufficient for mAb-mediated clearance of primary tumor challenge.
Clodronate Liposome-Sensitive Macrophages Mediate ADCC in the Context of hIgG1 and the Human FcgR System In the context of the mouse FcgR system, clodronate liposome (CLOD)-sensitive macrophages mediate ADCC of antibodycoated target cells (Uchida et al., 2004) . NK cells are dispensable for ADCC in this context, presumably because they do not express mFcgRI or mFcgRIV, but only express the low-affinity FcgR, FcgRIII, which interacts with msIgG2a antibodies with $40-fold lower affinity than mFcgRIV (Otten et al., 2008 Figure S6E ; p < 0.0001). With the exception of CD11c hi DCs (33% depletion, p = 0.01), no other cellular populations analyzed were affected by CLOD treatment ( Figure S6F ).
We first confirmed that depletion of blood and spleen B220 + B cells in hCD20-Tg mice (these mice express hCD20 on mature B cells and also express the full array of murine FcgRs) by mIgG2a isotype antihCD20 was dependent on CLOD-sensitive macrophages. Blood and spleen B cell numbers were decreased by 97.5%-98% and 63%-78% (p < 0.0001; Figure S7A ), respectively, in mice receiving either PBS or control liposomes plus mIgG2a antihCD20 mAb. By contrast, no B cells were depleted in mice receiving CLOD plus mIgG2a anti-hCD20 mAb. Thus, as described (Uchida et al., 2004) , ADCC of antibody-coated cells in vivo requires CLOD-sensitive macrophage populations.
We next tested the ability of hIgG1 (GASDALIE mutant) antihCD20 mAb to deplete hCD20 + B cells in the context of the human FcgR system in hCD20-Tg/FcgR-humanized mice (these mice express hCD20 on mature B cells and also express the full array of human FcgRs, but lack all murine FcgRs), as described above. Blood and spleen B cell numbers were decreased by 86%-90% and 81%-82% (p < 0.001), respectively, in hCD20-Tg/FcgR-humanized mice receiving either PBS or control liposomes plus hIgG1 (GASDALIE) anti-hCD20 mAb. By contrast, no B cells were depleted in mice receiving CLOD plus GASDALIE anti-hCD20 mAb ( Figure S7B ). Similar results were seen in FcgR-humanized mice treated with CLOD and a depleting hIgG1 (GASDALIE) anti-mCD4 mAb ( Figure S7C ). Therefore, CLOD-sensitive macrophages are required for ADCC mediated by hIgG1 antibody in the context of the human FcgR system. Figure 6A ) treated with anti-hCD20 mAb mutants that selectively engage only hFcgRIIIA (ALIE mutant) or both hFcgRIIA and hFcgRIIIA (GASDALIE mutant). Only 20% of FcgR-humanized mice receiving ALIE mutant anti-hCD20 mAb survived re-challenge with EL4-hCD20 cells, while 77% of mice receiving GASDALIE mutant anti-hCD20 mAb survived re-challenge (p < 0.0001; Figure 6B) . Further, only 36% (p = 0.01) of hFcgRIIIA/B-Tg mice (that lack all murine FcgRs and express only hFcgRIIIA and hFcgRIIIB) survive EL4-hCD20 re-challenge, again demonstrating that expression of hFcgRIIA is required for optimal induction of an anti-tumor vaccinal effect. Thus, engagement of hFcgRIIA, which is the only activating hFcgR expressed by human DCs, is required for the generation of an anti-tumor vaccinal effect by passively administered anti-tumor mAb.
DISCUSSION
It has long been hypothesized that passive administration of antitumor antibodies may generate immune complexes that, upon uptake by antigen-presenting cells, stimulate anti-tumor cellular immunity. Taken together, our results now mechanistically demonstrate how passively administered anti-tumor antibody achieves such an effect using a lymphoma cell line that expresses a model tumor neoantigen. Anti-tumor mAb opsonizes tumor cells and targets them for killing by FcgR-mediated ADCC, a process that generates antibody:tumor antigen immune complexes. These immune complexes engage activating FcgRs expressed by CD11c + antigen-presenting cells, which results in stimulation of DC maturation and presentation of tumor antigens to T cells, thereby leading to long-term anti-tumor cellular memory formation (Figure 7 ) (Boruchov et al., 2005; Dhodapkar et al., 2005; Kalergis and Ravetch, 2002; Nimmerjahn and Ravetch, 2008) . In the human FcgR system, the vaccinal effect requires interactions with hFcgRIIA, the sole activating FcgR expressed by DCs. Thus, these results now mechanistically explain how passively administered anti-tumor mAb stimulates anti-tumor cellular immune responses in vivo and suggest novel methods for augmenting such an effect.
It is clear that activating FcgRs expressed by antigen-presenting cells, especially DCs, are capable of capturing antibody/tumor antigen immune complexes. Upon immune complex binding, DCs undergo maturation, upregulate MHC-II and costimulatory molecules, and stimulate CD4 and CD8 T cells responses through traditional antigen presentation and crosspresentation Rafiq et al., 2002) . DCs loaded with antibody/tumor antigen immune complexes stimulate potent T cell responses that are capable of eradicating tumors (Kalergis and Ravetch, 2002) . In vitro studies have demonstrated that anti-CD20 mAb treatment of lymphoma cells stimulates DC maturation and CD8 T cell activation (Selenko et al., 2002) , and a synergistic effect between vaccination with hCD20 + tumor cells and anti-hCD20 mAb treatment has been demonstrated in mice (Gadri et al., 2009 (Table S2) . (B) hFcgRIIIA engagement mediates cytotoxic clearance of tumor cells by mAb. FcgR-humanized mice were given EL4-hCD20 cells and treated with hIgG1 mutant versions of anti-hCD20 mAb: GASDALIE mutant (enhanced engagement of hFcgRIIA and hFcgRIIIA; red circles; n = 20), GA mutant (preferential hFcgRIIA engagement; blue squares; n = 6), ALIE mutant (preferential hFcgRIIIA engagement; gray diamonds; n = 12), or PBS (black triangles; n = 17), with survival monitored daily. (C) hFcgRIIIA is necessary and sufficient to mediate the immediate cytotoxic clearance of EL4-hCD20 lymphoma cells. EL4-hCD20 cells were injected into hFCGR2A-Tg mice that were given GASDALIE mutant anti-hCD20 mAb (filled red circles; n = 11), hFCGR3A/B-Tg mice given GASDALIE mutant anti-hCD20 mAb (filled blue squares; n = 11), or wild-type mice given PBS (filled triangles; n = 10) with survival monitored daily.
considered to be excellent cross-presenters of cell-associated antigens (Mayer et al., 2014) , and soluble immune complexes stimulate cross-presentation by DCs more potently than antigen alone (Berlyn et al., 2001; Rafiq et al., 2002) . Correspondingly, a much larger fraction of CD8 + spleen CD11c hi cells expresses mFcgRIV compared to CD8
À
CD11c
hi cells (60% versus 28%, Figure S2E ), suggesting that CD8 + DCs may play a significant role during the induction of the mAb-mediated anti-tumor vaccinal effect. Further, clinical trials have shown that combining anti-CD20 mAb treatment with administration of immunomodulatory cytokines that promote the activation of DCs or T cell responses, such as IFN-a (Kimby et al., 2008) or GM-CSF (Cartron et al., 2008) , synergistically increased anti-CD20 mAb efficacy, suggesting that augmenting antigen presentation and T cell responses in the context of anti-tumor mAb therapy may augment an anti-tumor vaccinal effect. Murine studies have also demonstrated a heightened vaccinal effect when administration of the pleiotropic cytokine IL-2, which activates both innate cells and T cells, is combined with anti-hCD20 mAb treatment (Abè s et al., 2010). Thus, our studies now mechanistically explain how the anti-tumor cellular immune responses generated by passive antibody treatment are generated in vivo. While healthy individuals are normally tolerized to self-antigens such as CD20 and would not develop memory T cells reactive with self-antigens, cancer-bearing patients often break tolerance and autoimmune disorders are common in these patients (Abu-Shakra et al., 2001 ). Thus, while tolerance to overexpressed antigens, oncoproteins, tumor suppressor proteins, differentiation antigens, or neoantigens engaged by antibodies may be broken and lead to the generation of anti-tumor memory T cells, these cells are often anergized or exhausted and unable to mount an effective cytotoxic T cell response to the tumor. Activating these T cells to become effector cells and target tumor cells is thus a goal of (B) Surviving tumor-primed mice that received GASDALIE hIgG1 anti-hCD20 mAb (green circles; n = 28) or ALIE hIgG1 anti-hCD20 mAb (blue squares; n = 10) from Figure 5B , or naive mice (black triangles; n = 15) were re-challenged with EL4-hCD20 cells.
(C) Surviving tumor-primed FcgR-humanized (green circles; n = 28) or hFcgRIIIA/B-Tg mice (blue squares, n = 11) that received GASDALIE hIgG1 anti-hCD20 mAb from Figure 5C , or naive mice (black triangles; n = 10) were rechallenged with EL4-hCD20 cells. Significant differences between groups are indicated: **p < 0.01. current immunotherapy approaches, most recently achieved by blocking inhibitory signals such as CTLA-4 (Hodi et al., 2010) and PD-1 Topalian et al., 2012) . Our data support an alternative approach in which combining anti-tumor cytotoxic antibody therapeutics with various immunotherapies that boost cellular immune responses (i.e., agonistic anti-CD40 mAb) (Li and Ravetch, 2011) , or antagonistic anti-CTLA-4 or anti-PD-1 mAbs) may synergistically combine with an anti-tumor mAb vaccinal effect to boost cellular memory formation. Thus, our results suggest a general mechanism by which anti-tumor antibodies can stimulate anti-tumor cellular immune responses against a variety of tumor antigens. Significant efforts were put toward identifying the antigen-specific T cells that mediate the vaccinal effect in this study, but ex vivo re-stimulation (ELISPOT and intracellular cytokine staining) studies with tumor cell lysates, peptides, or irradiated tumor cells were not sensitive enough to detect rare tumor-specific T cells. Regardless, conclusions regarding the specificity of the anti-tumor vaccinal effect T cell response can be made. Mice primed with mAb and hCD20 + EL4 lymphoma cells rejected lymphoma re-challenge with hCD20 + EL4 cells but not wild-type EL4 cells ( Figure 1C ). This result suggests that the vaccinal effect T cell response is directed at the hCD20 neoantigen and that no detectable epitope-spreading occurs in this model. We have confirmed that the T cell response is, at least in part, directed at hCD20 because mice primed with mAb and hCD20 + EL4 lymphoma rejected re-challenge with a distinct tumor cell line expressing hCD20, but not the same cell line expressing a control antigen ( Figure 1D ). Whether all vaccinal effect anti-tumor T cell responses are solely directed at the mAb-targeted antigen, as in the current EL4 tumor model, or whether different tumor models or different tumor microenvironments (i.e., lymphoid versus solid tumors) will result in different mAb-induced anti-tumor T cell responses and epitope spreading remains unclear. Whether combining passive anti-tumor mAb with checkpoint inhibitor blockade or adjuvants will result in synergistically enhanced epitope spreading and anti-neoantigen T cell responses is also unknown. Our studies in FcgR-humanized mice with hIgG1 anti-hCD20 mAb-mediated ADCC of hCD20 + tumor cells clearly demonstrate that hFcgRIIIA is both necessary and sufficient for ADCC-mediated clearance of antibody-coated tumor cells; hFcgRIIA plays no role in this process ( Figure 5 ). These results correspond to findings in humans that FCGR3A polymorphisms correlate with response rates in lymphoma patients treated with anti-CD20 mAb (Cartron et al., 2002) or breast cancer patients treated with anti-Her2 mAb (Musolino et al., 2008) . Importantly, FcgR signaling is required for ADCC in vivo, rather than simple cross-linking of antigen (de Haij et al., 2010) . Because they solely express hFcgRIIIA, dogma has dictated that NK cells are the main mediators of ADCC in humans (Seidel et al., 2013) . Further promoting the belief that NK cells are the major mediators of ADCC in humans, NK cells from human peripheral blood are routinely used during in vitro ADCC assays, which inadequately attempt to artificially re-create a complex in vivo process. Nonetheless, it has been demonstrated that CLOD-sensitive macrophages (Uchida et al., 2004) (Figure S7A ), but not NK cells, are required for ADCC by mIgG in the context of murine FcgRs. This was partially thought to be due to the lone expression of FcgRIII on murine NK cells (Otten et al., 2008) , which weakly interacts with mouse antibody Fc compared to FcgRIV. Therefore, we have now clearly determined the cellular requirements for hIgG1-triggered ADCC mediated by human FcgRs and demonstrate that CLOD-sensitive macrophages mediate ADCC of antibody-coated target cells in vivo in the context of hIgG1 antibody and the human FcgR system (Figures S7B and S7C ). This result is significant, because new therapies aimed at augmenting human NK cell activity in vivo to enhance ADCC of mAb-targeted tumor cells are currently under investigation. Further studies determining any functional differences between murine and human NK cells will shed more light on this important matter. The results reported here highlight the importance of properly engineering antibody therapeutics to engage the appropriate FcgRs to mediate appropriate effector functions. Current efforts to augment anti-tumor antibodies have only focused on enhancing their cytotoxic effects by modulating hIgG1 Fc interactions with hFcgRIIIA to augment ADCC by innate cells, as exemplified by the next-generation glyco-engineered antihCD20 mAb, obinutuzumab (Goede et al., 2014) . Obinutuzumab is afucosylated for augmented affinity to only hFcgRIIIA, and accordingly, extends survival by $1 year in CLL patients when directly compared to an unmodified anti-CD20 antibody (Rituximab). However, afucosylation of obinutuzumab does not affect Fc engagement of hFcgRIIA, which is the sole activating hFcgR expressed on human antigen-presenting DCs for engagement of immune complexes and stimulation of T cell responses. Thus, our current results argue that an ideal anti-tumor therapeutic should not only optimally engage hFcgRIIIA for cytotoxic effector function, but also hFcgRIIA on DCs in order to induce long-term cellular anti-tumor immunity.
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EXPERIMENTAL PROCEDURES
Cell Lines and Mice EL4-WT and 293T cells were obtained from ATCC and maintained in Dulbecco's minimum essential medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies), 100 U/ml of penicillin, and 100 mg/ml of streptomycin (Life Technologies). EL4-hCD20 cells were obtained from Oliver Press (Fred Hutchinson Cancer Research Center, Seattle, WA) with permission from José e Golay (Ospedali Riuniti di Bergamo, Bergamo, Italy) and maintained in RPMI-1640 medium (Life Technologies) supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, and 100 mg/ml of streptomycin. B6BL cells, a spontaneous B cell lymphoma line isolated from p53 fl/fl CD19-Cre + mice on pure B6 genetic background, have been previously described (Robbiani et al., 2009 ) and were retrovirally transduced with constructs encoding either hCD20 or mCD20 (pVPack Vectors, Agilent Technologies), selected to make stable cell lines, and sorted for CD20 + cells, as described previously (Li and Ravetch, 2011) . C57BL/6 mice were purchased from Jackson Laboratories. Fcer1g -/- (Takai et al., 1994) , Fcgr4 -/- (Nimmerjahn et al., 2010) , FcRa null , FCGR3A/B-Tg (Li et al., 1996) 
Fcgr2b
À/À mice) mice on the C57BL/6 genetic background have been previously described. FcgR-humanized mice, which express all hFcgRs on the FcRa null C57BL/6 genetic background, have been described . Fcgr4 flox mice (Nimmerjahn et al., 2010) were crossed with mice expressing cre recombinase under the control of CD11c promoter/enhancer regions (B6.Cg-Tg(Itgax-cre)1-1Reiz/J mice, Jackson Laboratories). hCD20-Tg mice were kindly provided by Dr. Andrew Chan (Genentech) and crossed onto the FcgR-humanized background. All mice were maintained in a specific pathogen-free facility at the Rockefeller University, and all studies were approved by the Rockefeller University Institutional Animal Care and Use Committee.
Antibodies, Flow Cytometry, and Other Reagents
To generate CAT-13.6E12 and 2B8 mAb constructs, total RNA was obtained from hybridoma cells (DSMZ and ATCC, respectively), and cDNA was generated by using SuperscriptIII reverse transcriptase (Life Technologies) and immunoglobulin gene-specific primers. The V H and V K genes were amplified by PCR and cloned in frame into mammalian expression vectors with mouse IgG2a, mouse IgG1, mouse DA265 mutant, mouse Kappa, hIgG1, or huKappa Fc backbones. The human G236A, A330L/I332E, and GASDALIE Fc mutants were generated by site-directed mutagenesis with PCR amplification of the entire vector, using complementary primers containing the desired point mutations, as described (Li and Ravetch, 2011) . Antibodies were produced by transient transfection of 293T cells and subsequent protein G purification from culture supernatants, as described . AntimCD4 antibody (clone GK1.5) with a hIgG1 backbone and containing GASDALIE point mutations was generated previously . Fluorescently conjugated antibodies and staining procedures are listed in the Supplemental Experimental Procedures. To deplete macrophages in vivo, mice received 200 ml of clodronate liposomes or PBS liposomes intravenously (i.v.) through lateral tail veins (Clophosome-A, Formumax).
Tumor Model
For the primary tumor challenge, mice were injected i.v. through lateral tail veins with 5 3 10 5 EL4-hCD20 cells in 200 ml PBS on day 0. Mice then received intraperitoneal (i.p.) injections of 100 mg of antibody in 200 ml of PBS on days 1, 4, 7, 10, and 13. Survival was assessed daily. In some experiments, 90 days after primary tumor challenge, surviving mice were re-challenged i.v. with 5 3 10 6 EL4-hCD20 or EL4-WT cells, with survival assessed daily. In experiments in which hIgG1 antibodies or mutants were administered, FcgR-humanized mice were given 5 3 10 5 EL4-hCD20 cells in 200 ml PBS on day 0, with 250 mg of antibody in 200 ml of PBS given i.p. on days 1 and 2. Surviving mice were re-challenged with 5 3 10 6 EL4-hCD20 cells on day 60. In some experiments, mice were re-challenged i.v. with 5 3 10 4 B6BL cells expressing either hCD20 or mCD20. In adoptive transfer experiments, splenocytes from mice 30 days after primary tumor challenge were harvested and red blood cells were lysed. In some cases, CD3 + cells were negatively selected using magnetic beads (Miltenyi Biotec).
Then, 50 3 10 6 total splenocytes or 15 3 10 6 CD3 + cells were adoptively transferred into naive C57BL/6 mice. One day later, the mice were challenged with 5 3 10 5 EL4-hCD20 cells in 200 ml PBS, with survival assessed daily.
Statistics
Statistical differences between survival rates were analyzed by comparing Kaplan-Meier curves using the log-rank test and GraphPad Prism Software. All other statistical differences were compared using the Student's t test analysis. 
SUPPLEMENTAL INFORMATION
